(CCJ) Cameco - Overview
Sector: EnergyIndustry: Uranium | Exchange NYSE (USA) | Currency USD | Market Cap: 47.517m | Total Return 144.3% in 12m
Stock: Uranium, Fuel, Reactors
Total Rating 71
Risk 91
Buy Signal -1.02
| Risk 5d forecast | |
|---|---|
| Volatility | 49.7% |
| Relative Tail Risk | -4.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.83 |
| Alpha | 120.54 |
| Character TTM | |
|---|---|
| Beta | 1.866 |
| Beta Downside | 1.529 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.01% |
| CAGR/Max DD | 1.48 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 111.2449
Technicals: volatileDescription: CCJ Cameco March 05, 2026
Cameco Corporation (CCJ) supplies uranium for electricity generation across global markets, including the Americas, Europe, and Asia. The company operates through three segments: Uranium, Fuel Services, and Westinghouse.
The Uranium segment covers the entire process from exploration and mining to the sale of uranium concentrate. This segment is fundamental to the nuclear fuel cycle, which begins with uranium extraction.
Fuel Services refines, converts, and fabricates uranium concentrate, also managing conversion service transactions. Uranium conversion transforms yellowcake into uranium hexafluoride (UF6), a gas suitable for enrichment.
The Westinghouse segment functions as a nuclear reactor technology original equipment manufacturer (OEM) and service provider to utilities and government entities. This includes maintenance, engineering, and component supply for nuclear reactors. The nuclear power sector relies on OEMs like Westinghouse for reactor design, construction, and ongoing operational support.
Cameco sells its products and services directly to nuclear utilities. To delve deeper into CCJs operational specifics and financial health, consider exploring ValueRay.
Headlines to watch out for
- Global uranium prices directly impact Camecos revenue
- Nuclear power demand drives long-term uranium sales
- Regulatory changes affect uranium mining and processing costs
- Westinghouse acquisition expands nuclear technology services
- Geopolitical stability influences uranium supply chain reliability
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 589.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.17 > 1.0 |
| NWC/Revenue: 45.04% < 20% (prev 23.52%; Δ 21.52% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.39b > Net Income 589.4m |
| Net Debt (-91.9m) to EBITDA (1.05b): -0.09 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (435.5m) vs 12m ago -0.21% < -2% |
| Gross Margin: 29.40% > 18% (prev 0.25%; Δ 2.92k% > 0.5%) |
| Asset Turnover: 34.47% > 50% (prev 31.65%; Δ 2.81% > 0%) |
| Interest Coverage Ratio: 10.04 > 6 (EBITDA TTM 1.05b / Interest Expense TTM 74.5m) |
Altman Z'' 4.71
| A: 0.15 (Total Current Assets 2.64b - Total Current Liabilities 1.07b) / Total Assets 10.29b |
| B: 0.35 (Retained Earnings 3.61b / Total Assets 10.29b) |
| C: 0.07 (EBIT TTM 748.3m / Avg Total Assets 10.10b) |
| D: 1.97 (Book Value of Equity 6.69b / Total Liabilities 3.40b) |
| Altman-Z'' Score: 4.71 = AA |
Beneish M -3.16
| DSRI: 1.08 (Receivables 372.0m/309.6m, Revenue 3.48b/3.14b) |
| GMI: 0.85 (GM 29.40% / 24.96%) |
| AQI: 0.89 (AQ_t 0.42 / AQ_t-1 0.47) |
| SGI: 1.11 (Revenue 3.48b / 3.14b) |
| TATA: -0.08 (NI 589.4m - CFO 1.39b) / TA 10.29b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of CCJ shares?
As of March 29, 2026, the stock is trading at USD 103.92 with a total of 3,156,484 shares traded.
Over the past week, the price has changed by +2.33%, over one month by -12.23%, over three months by +11.93% and over the past year by +144.25%.
Over the past week, the price has changed by +2.33%, over one month by -12.23%, over three months by +11.93% and over the past year by +144.25%.
Is CCJ a buy, sell or hold?
Cameco has received a consensus analysts rating of 4.53.
Therefore, it is recommended to buy CCJ.
- StrongBuy: 10
- Buy: 9
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CCJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 124.3 | 19.6% |
| Analysts Target Price | 124.3 | 19.6% |
CCJ Fundamental Data Overview March 27, 2026
Market Cap CAD = 66.01b (47.52b USD * 1.3892 USD.CAD)
P/E Trailing = 111.2449
P/E Forward = 94.3396
P/S = 13.6467
P/B = 8.7973
P/EG = 1.9161
Revenue TTM = 3.48b CAD
EBIT TTM = 748.3m CAD
EBITDA TTM = 1.05b CAD
Long Term Debt = 996.3m CAD (from longTermDebt, last quarter)
Short Term Debt = 3.34m CAD (from shortTermDebt, last quarter)
Debt = 1.02b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -91.9m CAD (from netDebt column, last quarter)
Enterprise Value = 65.82b CAD (66.01b + Debt 1.02b - CCE 1.21b)
Interest Coverage Ratio = 10.04 (Ebit TTM 748.3m / Interest Expense TTM 74.5m)
EV/FCF = 62.48x (Enterprise Value 65.82b / FCF TTM 1.05b)
FCF Yield = 1.60% (FCF TTM 1.05b / Enterprise Value 65.82b)
FCF Margin = 30.26% (FCF TTM 1.05b / Revenue TTM 3.48b)
Net Margin = 16.93% (Net Income TTM 589.4m / Revenue TTM 3.48b)
Gross Margin = 29.40% ((Revenue TTM 3.48b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 22.24% (prev 37.32%)
Tobins Q-Ratio = 6.39 (Enterprise Value 65.82b / Total Assets 10.29b)
Interest Expense / Debt = 1.88% (Interest Expense 19.3m / Debt 1.02b)
Taxrate = 19.22% (47.3m / 246.2m)
NOPAT = 604.5m (EBIT 748.3m * (1 - 19.22%))
Current Ratio = 2.47 (Total Current Assets 2.64b / Total Current Liabilities 1.07b)
Debt / Equity = 0.15 (Debt 1.02b / totalStockholderEquity, last quarter 6.90b)
Debt / EBITDA = -0.09 (Net Debt -91.9m / EBITDA 1.05b)
Debt / FCF = -0.09 (Net Debt -91.9m / FCF TTM 1.05b)
Total Stockholder Equity = 6.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.84% (Net Income 589.4m / Total Assets 10.29b)
RoE = 8.76% (Net Income TTM 589.4m / Total Stockholder Equity 6.73b)
RoCE = 9.69% (EBIT 748.3m / Capital Employed (Equity 6.73b + L.T.Debt 996.3m))
RoIC = 7.82% (NOPAT 604.5m / Invested Capital 7.73b)
WACC = 12.38% (E(66.01b)/V(67.03b) * Re(12.55%) + D(1.02b)/V(67.03b) * Rd(1.88%) * (1-Tc(0.19)))
Discount Rate = 12.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.15%
[DCF] Terminal Value 68.63% ; FCFF base≈872.4m ; Y1≈1.08b ; Y5≈1.84b
[DCF] Fair Price = 37.84 (EV 16.39b - Net Debt -91.9m = Equity 16.48b / Shares 435.5m; r=12.38% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 47.76 | EPS CAGR: 96.11% | SUE: 1.49 | # QB: 1
Revenue Correlation: 76.99 | Revenue CAGR: 34.21% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=+0.005 | Chg30d=+0.014 | Revisions Net=-4 | Analysts=8
EPS current Year (2026-12-31): EPS=1.58 | Chg7d=-0.005 | Chg30d=+0.037 | Revisions Net=-1 | Growth EPS=+9.9% | Growth Revenue=+0.1%
EPS next Year (2027-12-31): EPS=2.56 | Chg7d=+0.002 | Chg30d=+0.045 | Revisions Net=-3 | Growth EPS=+62.0% | Growth Revenue=+16.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 11.7% (Discount Rate 12.6% - Earnings Yield 0.9%)
[Growth] Growth Spread = -9.3% (Analyst 2.3% - Implied 11.7%)
P/E Trailing = 111.2449
P/E Forward = 94.3396
P/S = 13.6467
P/B = 8.7973
P/EG = 1.9161
Revenue TTM = 3.48b CAD
EBIT TTM = 748.3m CAD
EBITDA TTM = 1.05b CAD
Long Term Debt = 996.3m CAD (from longTermDebt, last quarter)
Short Term Debt = 3.34m CAD (from shortTermDebt, last quarter)
Debt = 1.02b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -91.9m CAD (from netDebt column, last quarter)
Enterprise Value = 65.82b CAD (66.01b + Debt 1.02b - CCE 1.21b)
Interest Coverage Ratio = 10.04 (Ebit TTM 748.3m / Interest Expense TTM 74.5m)
EV/FCF = 62.48x (Enterprise Value 65.82b / FCF TTM 1.05b)
FCF Yield = 1.60% (FCF TTM 1.05b / Enterprise Value 65.82b)
FCF Margin = 30.26% (FCF TTM 1.05b / Revenue TTM 3.48b)
Net Margin = 16.93% (Net Income TTM 589.4m / Revenue TTM 3.48b)
Gross Margin = 29.40% ((Revenue TTM 3.48b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 22.24% (prev 37.32%)
Tobins Q-Ratio = 6.39 (Enterprise Value 65.82b / Total Assets 10.29b)
Interest Expense / Debt = 1.88% (Interest Expense 19.3m / Debt 1.02b)
Taxrate = 19.22% (47.3m / 246.2m)
NOPAT = 604.5m (EBIT 748.3m * (1 - 19.22%))
Current Ratio = 2.47 (Total Current Assets 2.64b / Total Current Liabilities 1.07b)
Debt / Equity = 0.15 (Debt 1.02b / totalStockholderEquity, last quarter 6.90b)
Debt / EBITDA = -0.09 (Net Debt -91.9m / EBITDA 1.05b)
Debt / FCF = -0.09 (Net Debt -91.9m / FCF TTM 1.05b)
Total Stockholder Equity = 6.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.84% (Net Income 589.4m / Total Assets 10.29b)
RoE = 8.76% (Net Income TTM 589.4m / Total Stockholder Equity 6.73b)
RoCE = 9.69% (EBIT 748.3m / Capital Employed (Equity 6.73b + L.T.Debt 996.3m))
RoIC = 7.82% (NOPAT 604.5m / Invested Capital 7.73b)
WACC = 12.38% (E(66.01b)/V(67.03b) * Re(12.55%) + D(1.02b)/V(67.03b) * Rd(1.88%) * (1-Tc(0.19)))
Discount Rate = 12.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.15%
[DCF] Terminal Value 68.63% ; FCFF base≈872.4m ; Y1≈1.08b ; Y5≈1.84b
[DCF] Fair Price = 37.84 (EV 16.39b - Net Debt -91.9m = Equity 16.48b / Shares 435.5m; r=12.38% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 47.76 | EPS CAGR: 96.11% | SUE: 1.49 | # QB: 1
Revenue Correlation: 76.99 | Revenue CAGR: 34.21% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=+0.005 | Chg30d=+0.014 | Revisions Net=-4 | Analysts=8
EPS current Year (2026-12-31): EPS=1.58 | Chg7d=-0.005 | Chg30d=+0.037 | Revisions Net=-1 | Growth EPS=+9.9% | Growth Revenue=+0.1%
EPS next Year (2027-12-31): EPS=2.56 | Chg7d=+0.002 | Chg30d=+0.045 | Revisions Net=-3 | Growth EPS=+62.0% | Growth Revenue=+16.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 11.7% (Discount Rate 12.6% - Earnings Yield 0.9%)
[Growth] Growth Spread = -9.3% (Analyst 2.3% - Implied 11.7%)